The company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new biosimilar launches in both emerging and developed markets, Arun Chandavarkar, managing director of Biocon Biologics, told ET in an interview.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3vzKZrV
via IFTTT
0 comments:
Post a Comment